Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Clinical trial NCT02785250 · UNKNOWN

Trial details

NCT number: NCT02785250
Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent Epithelial Ovarian Cancer Recurrent Fallopian Tube Cancer Recurrent Peritoneal Cancer

Start date: 2016-04-01
Primary completion: 2020-10-01
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.